Abstract
The use of pharmaceutical products produced by recombinant DNS technology has become a reality in today’s world. Brazil, however, has no pharmaceutical laboratory producing pharmaceutical products using this technology. This project intends to create a company able to produce pharmaceutical formulations using this method. The choice of the Human Growth Hormone (hGH) as the first product, …
